JOP20130342B1 - تكوين ثابت من بيميتركس - Google Patents
تكوين ثابت من بيميتركسInfo
- Publication number
- JOP20130342B1 JOP20130342B1 JOP/2013/0342A JOP20130342A JOP20130342B1 JO P20130342 B1 JOP20130342 B1 JO P20130342B1 JO P20130342 A JOP20130342 A JO P20130342A JO P20130342 B1 JOP20130342 B1 JO P20130342B1
- Authority
- JO
- Jordan
- Prior art keywords
- pemetrexed formulation
- stabilized pemetrexed
- stabilized
- formulation
- acetylcysteine
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 title abstract 3
- 229960005079 pemetrexed Drugs 0.000 title abstract 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
- 229960004308 acetylcysteine Drugs 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 150000001860 citric acid derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120137375A KR101260636B1 (ko) | 2012-11-29 | 2012-11-29 | 안정화된 페메트렉시드 제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20130342B1 true JOP20130342B1 (ar) | 2021-08-17 |
Family
ID=48665454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2013/0342A JOP20130342B1 (ar) | 2012-11-29 | 2013-11-27 | تكوين ثابت من بيميتركس |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9265832B2 (enExample) |
| EP (1) | EP2925325B1 (enExample) |
| JP (1) | JP5934448B2 (enExample) |
| KR (1) | KR101260636B1 (enExample) |
| CN (1) | CN104812392B (enExample) |
| AR (1) | AR093645A1 (enExample) |
| BR (1) | BR112015012460B1 (enExample) |
| CL (1) | CL2015001461A1 (enExample) |
| ES (1) | ES2656901T3 (enExample) |
| JO (1) | JOP20130342B1 (enExample) |
| MX (1) | MX355461B (enExample) |
| PH (1) | PH12015500900B1 (enExample) |
| RU (1) | RU2620341C2 (enExample) |
| TW (1) | TWI498128B (enExample) |
| WO (1) | WO2014084651A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012010774A1 (de) | 2012-05-31 | 2013-12-05 | Stada Arzneimittel Ag | Pharmazeutische Pemetrexed-Lösung |
| KR101485243B1 (ko) | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
| JP6094388B2 (ja) * | 2013-06-07 | 2017-03-15 | ニプロ株式会社 | ペメトレキセドを含む注射用組成物 |
| EP3040074B1 (en) * | 2013-10-03 | 2018-07-25 | Fujifilm Corporation | Injection preparation and method for producing same |
| JP6120766B2 (ja) * | 2013-12-27 | 2017-04-26 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
| KR101703980B1 (ko) | 2013-12-30 | 2017-02-08 | 주식회사 삼양바이오팜 | 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법 |
| PL3124026T3 (pl) * | 2014-03-28 | 2019-03-29 | Fujifilm Corporation | Preparat iniekcyjny i sposób jego wytwarzania |
| GB201418555D0 (en) * | 2014-10-16 | 2014-12-03 | Teva Gmbh | Pemetrexed formulations |
| KR101770605B1 (ko) * | 2014-11-17 | 2017-08-23 | 동아에스티 주식회사 | 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물 |
| KR101919436B1 (ko) | 2015-05-28 | 2018-11-16 | 주식회사 삼양바이오팜 | 안정화된 약학 조성물 및 그의 제조방법 |
| KR101693675B1 (ko) | 2015-12-14 | 2017-01-06 | 주식회사 종근당 | 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 |
| JP6837895B2 (ja) * | 2017-04-04 | 2021-03-03 | 日本化薬株式会社 | 医薬品溶液製剤の製造方法 |
| CN111093626A (zh) * | 2017-08-29 | 2020-05-01 | 费森尤斯卡比肿瘤学有限公司 | 培美曲塞的稳定的液体组合物 |
| KR102040034B1 (ko) | 2017-12-13 | 2019-11-05 | 주식회사 아이큐어비앤피 | 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법 |
| US10966982B2 (en) | 2018-11-20 | 2021-04-06 | Cipla Limited | Stable pharmaceutical formulations of pemetrexed |
| EP4132504A1 (en) * | 2020-04-09 | 2023-02-15 | Emphascience, Inc. | Methods of treatment using antifolates and pharmaceutical formulations comprising antifolates |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| CA2032695A1 (en) | 1989-12-20 | 1991-06-21 | Hiroshi Akimoto | Condensed heterocyclic compounds, their production and use |
| US6686365B2 (en) * | 2000-02-04 | 2004-02-03 | Eli Lilly And Company | Pharmaceutical composition |
| MXPA02007191A (es) | 2000-02-04 | 2002-12-09 | Lilly Co Eli | Composicion farmaceutica que comprende permetrexed junto con monotioglicerol, l-cisteina o acido tioglicolico. |
| KR100774366B1 (ko) | 2001-09-10 | 2007-11-08 | 주식회사 중외제약 | 파클리탁셀 주사제 조성물 |
| CH697021A5 (de) * | 2003-06-26 | 2008-03-31 | Merck Eprova Ag | Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat. |
| SI1574221T1 (sl) | 2004-03-10 | 2007-10-31 | Shimoda Biotech Pty Ltd | Stabilni sestavki diklofenaka za vbrizgavanje |
| DE602007011384D1 (de) * | 2006-08-14 | 2011-02-03 | Sicor Inc | Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure |
| US20090181990A1 (en) * | 2007-12-23 | 2009-07-16 | Patel Nileshkumar S | Stable amorphous form of pemetrexed disodium |
| JP2013540104A (ja) | 2010-07-28 | 2013-10-31 | イーグル・ファーマシューティカルズ・インコーポレーテッド | 延長された保存安定性を有するペメトレキセドを含有する医薬組成物 |
| KR101069128B1 (ko) * | 2011-03-10 | 2011-09-30 | 건일제약 주식회사 | 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법 |
| DE102012010774A1 (de) * | 2012-05-31 | 2013-12-05 | Stada Arzneimittel Ag | Pharmazeutische Pemetrexed-Lösung |
| KR101485243B1 (ko) * | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
-
2012
- 2012-11-29 KR KR1020120137375A patent/KR101260636B1/ko active Active
-
2013
- 2013-11-27 JO JOP/2013/0342A patent/JOP20130342B1/ar active
- 2013-11-28 AR ARP130104389A patent/AR093645A1/es not_active Application Discontinuation
- 2013-11-28 TW TW102143402A patent/TWI498128B/zh active
- 2013-11-29 MX MX2015006325A patent/MX355461B/es active IP Right Grant
- 2013-11-29 US US14/646,615 patent/US9265832B2/en active Active
- 2013-11-29 ES ES13858153.3T patent/ES2656901T3/es active Active
- 2013-11-29 RU RU2015122023A patent/RU2620341C2/ru active
- 2013-11-29 BR BR112015012460-7A patent/BR112015012460B1/pt active IP Right Grant
- 2013-11-29 WO PCT/KR2013/010967 patent/WO2014084651A1/en not_active Ceased
- 2013-11-29 JP JP2015544000A patent/JP5934448B2/ja active Active
- 2013-11-29 EP EP13858153.3A patent/EP2925325B1/en active Active
- 2013-11-29 CN CN201380062109.1A patent/CN104812392B/zh active Active
-
2015
- 2015-04-22 PH PH12015500900A patent/PH12015500900B1/en unknown
- 2015-05-29 CL CL2015001461A patent/CL2015001461A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI498128B (zh) | 2015-09-01 |
| CL2015001461A1 (es) | 2015-10-23 |
| KR101260636B1 (ko) | 2013-05-13 |
| MX2015006325A (es) | 2016-02-25 |
| EP2925325A4 (en) | 2016-07-13 |
| CN104812392A (zh) | 2015-07-29 |
| WO2014084651A1 (en) | 2014-06-05 |
| US20150297724A1 (en) | 2015-10-22 |
| EP2925325B1 (en) | 2017-11-01 |
| US9265832B2 (en) | 2016-02-23 |
| ES2656901T3 (es) | 2018-02-28 |
| RU2620341C2 (ru) | 2017-05-24 |
| BR112015012460B1 (pt) | 2022-04-05 |
| JP5934448B2 (ja) | 2016-06-15 |
| MX355461B (es) | 2018-04-19 |
| PH12015500900A1 (en) | 2015-07-06 |
| AR093645A1 (es) | 2015-06-17 |
| CN104812392B (zh) | 2017-05-17 |
| HK1212224A1 (en) | 2016-06-10 |
| JP2016500099A (ja) | 2016-01-07 |
| TW201434493A (zh) | 2014-09-16 |
| RU2015122023A (ru) | 2017-01-10 |
| BR112015012460A2 (enExample) | 2017-08-22 |
| PH12015500900B1 (en) | 2015-07-06 |
| EP2925325A1 (en) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500900B1 (en) | A stabilized pemetrexed formulation | |
| MX2013012542A (es) | Compuestos de amida y aplicacion farmaceutica para el mismo. | |
| PH12016500586A1 (en) | Stabilized efinaconazole compositions | |
| IL234014A0 (en) | Cycloalkane derivatives, preparations containing them and their uses | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2015002040A (es) | Baricitinib deuterado. | |
| SG11201506149SA (en) | Polyetheramines based on 1,3-dialcohols | |
| PL2984076T3 (pl) | Estry i etery 2,5-tetrahydrofuranu jako plastyfikatory | |
| CA2905610C (en) | Hyaluronic acid derivatives | |
| IL233824A (en) | Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use | |
| IL242195B (en) | Dicarboxylic acid compounds, preparations containing them and their uses | |
| WO2013123046A3 (en) | Cathode buffer materials and related devices and methods | |
| CA2875305C (en) | Fbxo3 inhibitors | |
| IL237542B (en) | Amphiphilic compounds, their preparations and uses | |
| IL233682A0 (en) | Modified phenylazole derivatives, preparations containing them and their uses | |
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. | |
| MY175703A (en) | Tablets with improved acceptance and good storage stability | |
| IL267888B (en) | Amphiphilic compounds, their preparations and uses | |
| IL237540B (en) | Amphiphilic compounds, their preparations and uses | |
| IL237539A0 (en) | Amphiphilic compounds, their preparations and uses | |
| IL237538B (en) | Amphiphilic compounds, their preparations and uses | |
| EP3057972A4 (en) | Novel compositions, uses and methods for their preparation | |
| UA80812U (en) | ETHYL 6-THIOXO-3-(2-FURYLMETHYL)-7-CYANO-1,3,4,6-2H-PYRIDO[1,2-a][1,3,5]TRIAZINE -9-CARBOXYLATE | |
| UA86158U (en) | Antibacterial agent | |
| IN2013CH00453A (enExample) |